Acquisitions5 May 2025, 05:09 pm
Senores Pharmaceuticals Acquires ANDA for Topiramate HCI 25, 50, 100 and 200 mg tablets from Wockhardt
AI Summary
Senores Pharmaceuticals Limited, through its wholly-owned subsidiary Senores Pharmaceuticals, Inc., USA, has signed an agreement to acquire the USFDA-approved Abbreviated New Drug Application (ANDA) for Topiramate HCI 25, 50, 100 and 200 mg tablets from Wockhardt Limited. The acquisition will be funded through the Initial Public Offer (IPO) proceeds. Topiramate is indicated as a treatment for epilepsy and migraine. The market size of Topiramate Tablet in the USA was ~USD 111.47 Mn (MAT December 2024) as per IQVIA.
Key Highlights
- Senores Pharmaceuticals Limited has acquired USFDA-approved ANDA for Topiramate HCI 25, 50, 100 and 200 mg tablets from Wockhardt Limited.
- The acquisition will be funded through the Initial Public Offer (IPO) proceeds.
- Topiramate is indicated as a treatment for epilepsy and migraine.
- The market size of Topiramate Tablet in the USA was ~USD 111.47 Mn (MAT December 2024) as per IQVIA.
- Senores Pharmaceuticals Limited is a global, research-driven pharmaceutical company with a wide range of pharmaceutical products and a strong R&D capabilities.